Catherine Owen serves as the Chief Executive Officer at ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. With a robust background in the pharmaceutical industry, Owen brings a wealth of experience and leadership to her role at ACADIA. Prior to joining ACADIA, she held several high-level positions at other prominent pharmaceutical companies, where she demonstrated her ability to drive growth and innovation. Before becoming CEO, Owen served as the Chief Commercial Officer at ACADIA, where she played a pivotal role in the successful launch and commercialization of the company's flagship product, NUPLAZID, which is used to treat hallucinations and delusions associated with Parkinson's disease psychosis. Her strategic vision and deep understanding of the market have been instrumental in positioning ACADIA as a leader in the CNS disorder space. Under her leadership, ACADIA has expanded its pipeline and pursued new therapeutic areas, further solidifying its commitment to improving patient outcomes. As CEO, Catherine Owen continues to steer ACADIA towards new heights, focusing on advancing the company's research and development efforts while maintaining a strong emphasis on patient-centric care. Her leadership style is characterized by a collaborative approach, fostering a culture of innovation and excellence within the organization. Owen's dedication to the company's mission and her proven track record of success make her an invaluable asset to ACADIA Pharmaceuticals Inc. as it continues to grow and make significant strides in the field of neuroscience.